 Lynn Hassman
Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 7 | 2025 | 150 | 1.660 |
Why?
| | Eye Infections, Viral | 2 | 2026 | 12 | 1.510 |
Why?
| | Uveitis, Anterior | 3 | 2025 | 27 | 1.150 |
Why?
| | Scleritis | 3 | 2025 | 28 | 1.130 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2026 | 22 | 0.930 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 8 | 0.920 |
Why?
| | Keratitis | 1 | 2025 | 20 | 0.910 |
Why?
| | Laser Coagulation | 1 | 2026 | 80 | 0.890 |
Why?
| | Retinal Detachment | 1 | 2026 | 73 | 0.880 |
Why?
| | Eye Infections, Bacterial | 1 | 2025 | 45 | 0.880 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2026 | 130 | 0.870 |
Why?
| | Papilledema | 1 | 2024 | 44 | 0.780 |
Why?
| | Optic Disk | 1 | 2024 | 53 | 0.780 |
Why?
| | Retinal Diseases | 1 | 2021 | 101 | 0.640 |
Why?
| | Metagenome | 1 | 2021 | 126 | 0.620 |
Why?
| | Eye Diseases | 1 | 2021 | 97 | 0.600 |
Why?
| | Metagenomics | 1 | 2021 | 150 | 0.600 |
Why?
| | Visual Acuity | 4 | 2026 | 490 | 0.580 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2021 | 238 | 0.580 |
Why?
| | Panophthalmitis | 1 | 2018 | 2 | 0.570 |
Why?
| | Vitreous Body | 1 | 2018 | 117 | 0.540 |
Why?
| | Herpes Simplex | 1 | 2018 | 99 | 0.530 |
Why?
| | Herpesvirus 1, Human | 1 | 2018 | 84 | 0.520 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 270 | 0.370 |
Why?
| | Herpesvirus 8, Human | 2 | 2012 | 67 | 0.340 |
Why?
| | Palatine Tonsil | 1 | 2011 | 54 | 0.320 |
Why?
| | Plasma Cells | 1 | 2011 | 80 | 0.320 |
Why?
| | Adalimumab | 2 | 2025 | 54 | 0.280 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.240 |
Why?
| | Fluorescein Angiography | 2 | 2026 | 189 | 0.240 |
Why?
| | B-Lymphocytes | 1 | 2011 | 872 | 0.220 |
Why?
| | Atrophy | 1 | 2025 | 199 | 0.220 |
Why?
| | Tertiary Care Centers | 1 | 2026 | 195 | 0.220 |
Why?
| | Receptors, CCR6 | 1 | 2024 | 4 | 0.210 |
Why?
| | Withholding Treatment | 1 | 2025 | 80 | 0.210 |
Why?
| | HLA-B27 Antigen | 1 | 2024 | 16 | 0.210 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5428 | 0.210 |
Why?
| | Adult | 8 | 2026 | 40882 | 0.200 |
Why?
| | Cell Proliferation | 1 | 2011 | 2514 | 0.190 |
Why?
| | Cell Differentiation | 1 | 2011 | 2050 | 0.190 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1043 | 0.190 |
Why?
| | HLA-B Antigens | 1 | 2022 | 58 | 0.180 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.180 |
Why?
| | Glucocorticoids | 1 | 2026 | 532 | 0.170 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 478 | 0.170 |
Why?
| | Humans | 18 | 2026 | 145785 | 0.170 |
Why?
| | Vision, Ocular | 1 | 2021 | 47 | 0.170 |
Why?
| | Central Nervous System Diseases | 1 | 2022 | 74 | 0.170 |
Why?
| | Macrophages, Peritoneal | 1 | 2021 | 89 | 0.170 |
Why?
| | Retrospective Studies | 5 | 2026 | 17330 | 0.170 |
Why?
| | Eye Proteins | 1 | 2021 | 92 | 0.160 |
Why?
| | Sarcoidosis | 1 | 2022 | 163 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 673 | 0.140 |
Why?
| | Gene Expression | 2 | 2021 | 1478 | 0.140 |
Why?
| | Male | 8 | 2026 | 73012 | 0.140 |
Why?
| | Middle Aged | 6 | 2026 | 36309 | 0.130 |
Why?
| | Diagnosis, Differential | 2 | 2020 | 1512 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 534 | 0.130 |
Why?
| | Precision Medicine | 1 | 2021 | 461 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 1042 | 0.130 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 364 | 0.120 |
Why?
| | Female | 9 | 2026 | 79045 | 0.120 |
Why?
| | Peptides | 1 | 2022 | 1000 | 0.120 |
Why?
| | Autoimmunity | 1 | 2022 | 933 | 0.120 |
Why?
| | Computational Biology | 1 | 2021 | 669 | 0.120 |
Why?
| | Chemokines, CC | 2 | 2006 | 33 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2024 | 4568 | 0.110 |
Why?
| | MicroRNAs | 1 | 2021 | 686 | 0.110 |
Why?
| | Ultrasonography | 1 | 2018 | 788 | 0.110 |
Why?
| | RNA | 1 | 2021 | 912 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1507 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2601 | 0.090 |
Why?
| | Poly(A)-Binding Protein I | 1 | 2012 | 1 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 923 | 0.090 |
Why?
| | RNA, Nuclear | 1 | 2012 | 5 | 0.090 |
Why?
| | Algorithms | 1 | 2020 | 1851 | 0.090 |
Why?
| | Cytoplasm | 1 | 2012 | 254 | 0.090 |
Why?
| | Lymphoma, Primary Effusion | 1 | 2011 | 4 | 0.080 |
Why?
| | Castleman Disease | 1 | 2011 | 16 | 0.080 |
Why?
| | Aging | 1 | 2021 | 1973 | 0.080 |
Why?
| | Disease Transmission, Infectious | 1 | 2011 | 69 | 0.080 |
Why?
| | Young Adult | 2 | 2025 | 14254 | 0.080 |
Why?
| | Antigens, Viral | 1 | 2011 | 182 | 0.080 |
Why?
| | Aged | 3 | 2025 | 26217 | 0.080 |
Why?
| | Viral Proteins | 1 | 2012 | 350 | 0.070 |
Why?
| | RNA, Messenger | 2 | 2021 | 2805 | 0.070 |
Why?
| | Genome, Viral | 1 | 2011 | 214 | 0.070 |
Why?
| | Cell Nucleus | 1 | 2012 | 588 | 0.070 |
Why?
| | RNA, Viral | 1 | 2012 | 693 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2770 | 0.070 |
Why?
| | Adolescent | 2 | 2026 | 22577 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2006 | 48 | 0.060 |
Why?
| | Bronchial Hyperreactivity | 1 | 2006 | 104 | 0.060 |
Why?
| | Nuclear Proteins | 1 | 2011 | 740 | 0.060 |
Why?
| | Flow Cytometry | 2 | 2024 | 1165 | 0.060 |
Why?
| | Interleukin-13 | 1 | 2006 | 146 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 44 | 0.060 |
Why?
| | Chemokines, CXC | 1 | 2004 | 68 | 0.050 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 119 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2024 | 40 | 0.050 |
Why?
| | Eosinophils | 1 | 2006 | 316 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 233 | 0.050 |
Why?
| | Integrins | 1 | 2024 | 90 | 0.050 |
Why?
| | Intraocular Pressure | 1 | 2026 | 330 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 782 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2011 | 4151 | 0.050 |
Why?
| | Synovial Fluid | 1 | 2022 | 67 | 0.050 |
Why?
| | Cross Reactions | 1 | 2022 | 130 | 0.050 |
Why?
| | Peptide Library | 1 | 2022 | 91 | 0.050 |
Why?
| | Animals | 6 | 2024 | 38106 | 0.050 |
Why?
| | Amino Acid Motifs | 1 | 2022 | 219 | 0.050 |
Why?
| | Trans-Activators | 1 | 2004 | 396 | 0.040 |
Why?
| | Spondylitis, Ankylosing | 1 | 2022 | 43 | 0.040 |
Why?
| | Lung | 2 | 2006 | 4116 | 0.040 |
Why?
| | Thioglycolates | 1 | 2021 | 3 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2021 | 3130 | 0.040 |
Why?
| | Gene Expression Profiling | 3 | 2021 | 1777 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2025 | 2028 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2021 | 181 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 838 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 11794 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 338 | 0.040 |
Why?
| | Chronic Disease | 2 | 2021 | 1812 | 0.040 |
Why?
| | Autoantigens | 1 | 2022 | 427 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1454 | 0.040 |
Why?
| | Lung Diseases | 1 | 2006 | 782 | 0.040 |
Why?
| | Cellular Senescence | 1 | 2021 | 226 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 442 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 318 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2021 | 361 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2004 | 1482 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2022 | 1146 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 994 | 0.030 |
Why?
| | Inflammation | 2 | 2021 | 2885 | 0.030 |
Why?
| | Mice | 4 | 2021 | 18358 | 0.030 |
Why?
| | Asthma | 1 | 2004 | 1797 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3634 | 0.020 |
Why?
| | Allergens | 2 | 2006 | 386 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 2012 | 73 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2012 | 318 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 365 | 0.020 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 148 | 0.020 |
Why?
| | RNA, Untranslated | 1 | 2012 | 121 | 0.020 |
Why?
| | Child, Preschool | 1 | 2026 | 11868 | 0.020 |
Why?
| | Protein Transport | 1 | 2012 | 442 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5995 | 0.020 |
Why?
| | Virus Replication | 1 | 2012 | 521 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4302 | 0.020 |
Why?
| | Cytokines | 2 | 2006 | 2069 | 0.020 |
Why?
| | Receptors, CCR3 | 1 | 2006 | 7 | 0.020 |
Why?
| | Chemokine CCL11 | 1 | 2006 | 25 | 0.020 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2006 | 64 | 0.010 |
Why?
| | Receptors, Cytokine | 1 | 2006 | 36 | 0.010 |
Why?
| | Cathepsins | 1 | 2006 | 24 | 0.010 |
Why?
| | Child | 1 | 2026 | 22740 | 0.010 |
Why?
| | Mucus | 1 | 2006 | 75 | 0.010 |
Why?
| | Doxycycline | 1 | 2006 | 62 | 0.010 |
Why?
| | Mast Cells | 1 | 2006 | 148 | 0.010 |
Why?
| | STAT6 Transcription Factor | 1 | 2004 | 24 | 0.010 |
Why?
| | Chemokine CXCL9 | 1 | 2004 | 38 | 0.010 |
Why?
| | Chemokine CXCL10 | 1 | 2004 | 39 | 0.010 |
Why?
| | STAT1 Transcription Factor | 1 | 2004 | 66 | 0.010 |
Why?
| | Ligands | 1 | 2006 | 668 | 0.010 |
Why?
| | Ovalbumin | 1 | 2004 | 194 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2006 | 751 | 0.010 |
Why?
| | Eosinophilia | 1 | 2006 | 224 | 0.010 |
Why?
| | Down-Regulation | 1 | 2004 | 618 | 0.010 |
Why?
| | Cell Movement | 1 | 2006 | 963 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1261 | 0.010 |
Why?
| | Up-Regulation | 1 | 2004 | 848 | 0.010 |
Why?
| | Kinetics | 1 | 2004 | 1568 | 0.010 |
Why?
| | Mice, Transgenic | 1 | 2006 | 2192 | 0.010 |
Why?
| | Signal Transduction | 1 | 2004 | 5226 | 0.010 |
Why?
|
|
Hassman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|